Recombinant Mouse Hdac6 Protein, MYC/DDK-tagged

• Cat.No.: Hdac6-1104M
• Product Overview: Purified recombinant protein of full-length mouse histone deacetylase 6 (cDNA clone MGC:46887 IMAGE:5352032), complete cds, with C-terminal MYC/DDK tag, was expressed in HEK293T cells.

Specification

• Description: Ubiquitous expression in genital fat pad adult (RPKM 65.5), whole brain E14.5 (RPKM 26.3) and 27 other tissues.
• Source: HEK293T
• Species: Mouse
• Tag: Myc&DDK
• Molecular Mass: 147.2 kDa
• Purity: >80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade after receiving vials.
• Concentration: >50 µg/mL as determined by microplate BCA method
• Storage Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.

Gene Information

• Gene Name: Hdac6 histone deacetylase 6 [ Mus musculus (house mouse) ]
• Official Symbol: Hdac6
• Synonyms: Hdac6; histone deacetylase 6; Hd6; Sfc6; Hdac5; mHDA2; histone deacetylase 6; histone deacetylase 5; histone deacetylase mHDA2; scurfy candidate 6; tubulin-lysine deacetylase HDAC6; EC 3.5.1.98
• Gene ID: 15185
• mRNA Refseq: NM_010413
• Protein Refseq: NP_034543
• UniProt ID: Q9Z2V5

Reviews

06/23/2019

Their expertise and guidance have helped overcome hurdles, ensuring the smooth progress of my research.

12/07/2018

The bands of proteins in Western Blotting experiments were very clear.

09/16/2018

Its purity and consistency have provided me with reliable and reproducible results, ensuring the accuracy of my research findings.

Q&As

Can HDAC6 inhibitors be used in combination with other therapies, and if so, what synergistic effects are expected?

Yes, HDAC6 inhibitors can be combined with other therapies for enhanced efficacy. Synergistic effects may include improved anti-cancer activity or neuroprotection.

Are there any ongoing clinical trials targeting HDAC6, and if so, what are the potential outcomes for patients?

Yes, there are clinical trials exploring HDAC6 inhibitors as potential treatments. Positive outcomes could lead to new therapeutic options for patients.

In what other diseases has HDAC6 been implicated, and how might this knowledge be applied clinically?

HDAC6 is implicated in neurodegenerative diseases and inflammatory disorders. Understanding its role could lead to novel therapeutic approaches for these conditions.

How does HDAC6 influence cellular processes, and why is this relevant in a clinical setting?

HDAC6 regulates cell motility, protein trafficking, and other processes. Understanding these mechanisms is crucial for developing targeted therapies in various diseases.

Are there any known genetic variations in HDAC6, and how might these impact individual responses to treatments in a clinical setting?

Genetic variations in HDAC6 may influence individual responses to treatments. Personalized medicine approaches could consider these variations for better outcomes.